Our team

A global team with world-class experience.

Paul Hopper

Executive Chairman
Read full bio

Paul Hopper

Executive Chairman

Paul is the Founder of Radiopharm Theranostics. He has over 25 years experience in the biotech, healthcare & life sciences sectors. Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO of more than fifteen companies in the US, Australia and Asia. Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma and Arovella Therapeutics. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances.

Riccardo Canevari

Managing Director and Chief Executive Officer
Read full bio

Riccardo Canevari

Managing Director and Chief Executive Officer

Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals.  He was most recently Chief Commercial Officer of Novartis company Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia.  He was lead for Lutathera in-market growth strategy and execution to build a blockbuster asset and lead on the prelaunch plan for Lu-PSMA 617 in metastatic prostate cancer.  He assessed Go To Market Models for each priority country and access to other markets.  Prior to this Riccardo was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products including KISQALI and PIQRAY.  He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.

Professor David Mozley

Chief Medical Officer & Scientific Advisory Board Chair
Read full bio

Professor David Mozley

Chief Medical Officer & Scientific Advisory Board Chair

David is a Professor of Nuclear Medicine with 30+ years in the nuclear medicine field. He was most recently at Cornell University where he was Chief of Nuclear Medicine and single-site Principal Investigator for first-in-human pharmaceutical industry contracts from three different companies using novel radiopharmaceuticals as major endpoints.  He was also the Physician Sponsor of 10 investigational new drug applications.  At University Pennsylvania he was PI awarded more than $8M in NIH RO1 grants relating to radiopharmaceutical development.  He has participated in over 60 clinical trials at Eli Lily and over 100 trials at Merck in novel radiopharmaceutical development.  Previously he was at Endocyte as Vice President of Imaging, coordinating efforts to take imaging based theranostics to market.  He has co-authored more than 100 peer-reviewed publications mostly focused on radiopharmaceutical development and is widely renowned as a Board Certified physician.

Dr Thom Tulip

Chief Technology Officer
Read full bio

Dr Thom Tulip

Chief Technology Officer

Thom has spent more than 25 years in the development and commercialisation of radiopharmaceuticals and imaging agents. He has served in senior leadership roles at Navidea BioPharmaceuticals Inc, Alseres Pharmaceuticals, Lantheus Medical Imaging (LMI), Bristol Myers Squibb (BMS) and DuPont. He was a Board Member of the Academy of Molecular Imaging and Chairperson of its Institute for Molecular Technologies.  Dr Tulip was Chairperson of the Society of Nuclear Medicine Corporate Advisory Board and served as a Director of the Council of Radionuclides and Radiopharmaceuticals.  He serves on the Board of Directors of the Medical Imaging Technology Association (MITA).

Antje Wegener

Vice President Clinical Development
Read full bio

Antje Wegener

Vice President Clinical Development

Joining RAD on 1 March 2022, Antje has spent her entire professional career in drug development, having held positions of progressively increasing responsibility at both large pharmaceutical companies and small biotechnology groups. She brings a broad expertise in oncology clinical development in both solid tumors and hematological diseases with a main focus on early clinical development of various compounds such as radioligand imaging and therapies, nanoparticles, bispecific antibodies and targeted therapies.  She was until recently Senior Development Medical Director at Novartis, working on radiopharmaceutical compounds for imaging and therapies. Prior to this she was Global Clinical Program Leader at Advanced Accelerator Applications, Global Head of Development at Nanobiotix, International Project Director at Servier and Global Clinical Lead at Novartis. Ms Wegener has a strong background in Drug Safety/Pharmacovigilance as Brand Safety Leader at Novartis, Director of Drug Safety & Pharmacovigilance at the Cancer International Research Group and Head of Drug Safety at Bayer France.


Dr Gitasha Chand

Global Medical Director
Read full bio

Dr Gitasha Chand

Global Medical Director

Dr. Chand is a physician with special expertise in radiopharmaceutical drug development. At NanoMab Technology Limited, she heads the Clinical Research department where she successfully planned and oversaw the completion of two early Phase 1 studies in Shanghai, targeting PD-L1 expression in non-small cell lung cancer and HER2 expression in breast cancer. She previously worked on the Phase 2 clinical development of 188-Re HEDP, a radiopharmaceutical for palliative treatment of metastatic bone disease. Earlier in her career, she was a resident trainee physician at Shanghai East Hospital specialising in emergency and disaster medicine.  


Dr Levente Meszaros

Global Director of Translational Science
Read full bio

Dr Levente Meszaros

Global Director of Translational Science

Dr Meszaros is an expert in molecular imaging and radioconjugate development. He is Director of Technical Operations at NanoMab Technology, overseeing non-clinical tracer development, technology transfer and GMP manufacturing of small molecules. Prior to joining NanoMab, Dr Meszaros worked as project leader at BioProbe Ltd, a non-clinical CRO, and as quality control scientist at Theragnostics Ltd. Earlier in his career, he was a research associate at King’s College London, where his research focused on the development of radiolabelled peptide hormones. 


Dr Scot Harper

Senior Vice President of Clinical Operations
Read full bio

Dr Scot Harper

Senior Vice President of Clinical Operations

Dr. Harper has spent his entire professional career in drug development, having held positions at the VP level with companies including Eli Lilly, Novartis and Parexel.  He was also the SVP of Clinical Development at Endocyte, working on radiopharmaceutical imaging and therapies. 


Bill Regan

Senior Vice President Regulatory Strategy
Read full bio

Bill Regan

Senior Vice President Regulatory Strategy

Bill has more than 40 years of experience in Compliance, Quality, Manufacturing, Change Control and Regulatory Affairs in the pharmaceutical and biotech industry. Until recently Bill was Chief Compliance Officer and Senior Vice President for Global Regulatory and Quality at Navidea Biopharmaceuticals.   Prior to Navidea, Bill was the Principal at Regan Advisory Services LLC and Global Regulatory Advisory Services LLC.  He also served as Head of Global Regulatory Affairs for Bristol Myers Squibb Medical Imaging.  Bill has held various board positions including PharmaPros, E Clinical Insights and the Council on Radionuclides and Radiopharmaceuticals.  Bill is a Trustee of the Regan Family Fund for Giving and is also an honorary board member and on the Business Advisory Council of Mass Down Syndrome Congress in Burlington Massachusetts.


Phillip Hains

Chief Financial Officer & Company Secretary
Read full bio

Phillip Hains

Chief Financial Officer & Company Secretary

Phillip is a Chartered Accountant operating a specialist public practice, ‘The CFO Solution’.  The CFO Solution focuses on providing back office support, financial reporting and compliance systems for listed public companies (particularly biotechnology companies).  Phillip has over 25 years experience in providing businesses with accounting administration, compliance and general management services.

Alison Gartner

Project Manager
Read full bio

Alison Gartner

Project Manager

Alison has over 20 years experience as a biotech analyst and life science investor across ASX listed and private companies through her investment management roles at Asia Union Investments and life science fund BioScience Managers. She is experienced in the establishment of VC and life science funds, and the portfolio management of assets from private start-ups through to FDA approvals, including involvement in private and public ASX capital raisings. Ms Gartner is a Director of the National Foundation of Medical Research and Innovation, Project Manager at Chimeric Therapeutics and co-founder of Evidentli Pty Ltd.

Paul Hopper

Executive Chairman
Read full bio

Paul Hopper

Executive Chairman

Paul is the Founder of Radiopharm Theranostics. He has over 25 years experience in the biotech, healthcare & life sciences sectors. Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO of more than fifteen companies in the US, Australia and Asia. Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma and Arovella Therapeutics. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances.

Riccardo Canevari

Managing Director and Chief Executive Officer
Read full bio

Riccardo Canevari

Managing Director and Chief Executive Officer

Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals.  He was most recently Chief Commercial Officer of Novartis company Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia.  He was lead for Lutathera in-market growth strategy and execution to build a blockbuster asset and lead on the prelaunch plan for Lu-PSMA 617 in metastatic prostate cancer.  He assessed Go To Market Models for each priority country and access to other markets.  Prior to this Riccardo was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products including KISQALI and PIQRAY.  He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.

Hester Larkin

Non-Executive Director
Read full bio

Hester Larkin

Non-Executive Director

Ms Larkin has a 30-year career spanning both pharmaceuticals and nuclear medicine across Europe, Middle East & Africa, including over 12 years experience in senior leadership roles in the industry.  She brings a proven track record of leading successful product launches of proprietary pharmaceuticals and imaging agents in oncology, cardiology, neurology and HIV.  Ms Larkin is currently MD of Hester Larkin Associates Consulting where she consults to diagnostic imaging, pharmaceutical and biotech companies on pre-clinical, clinical, EMA submission, EU medical advisory boards, EU manufacturing and commercial partnerships. She has held several Director and Trustee positions in the UK and Belgium and currently sits on the Board of 3 Charities. She was a business consultant at the Cardiac Imaging Department, Wellington Hospital when it launched the first Electron Beam CT (EBCT) centre.  Ms Larkin was previously EMEA General Manager BMS Medical Imaging at Bristol-Myers Squibb and had a 19-year career at DuPont Pharmaceuticals holding several roles in European marketing, European Business development and General Management & VP positions. She was the first non-American female to be appointed as Managing Director & Vice President UK & Ireland for Dupont Pharmaceuticals. For 7 years Ms Larkin also chaired an Industry Working Group on Nuclear Medicine Awareness for ‘Nuclear Medicine Europe-the Industry Association,’ formerly AIPES. With a legal background Ms Larkin has experience in governance, risk, acquisitions, mergers, licensing & divestitures.


Ian Turner

Non-Executive Director
Read full bio

Ian Turner

Non-Executive Director

Ian is a highly experienced radiopharmaceutical and nuclear medicine supply and manufacturing expert with a distinguished C-level career across some of the leading corporations in the sector including CEO and President of Siemens PETNET Solutions from 2010-2012. Prior to that role he was General Manager of ANSTO Radiopharmaceuticals in Sydney Australia, Australia's leading manufacturer of radioisotopes for the nuclear medicine sector.  He was also Executive Director of PETNET Australia Pty Ltd.  He spent a decade in various C-level roles at Varian Inc in Palo Alto and Melbourne.  Ian was also previously a Director of Coqui Pharmaceuticals until 2019, a company involved in the supply of radioisotopes in the US.

Dr Michael Baker

Non-Executive Director
Read full bio

Dr Michael Baker

Non-Executive Director

Michael is currently CEO and MD of ASX listed Arovella Therapeutics which is developing technologies in the cell therapy and drug delivery fields.  Prior to Arovella he was an Investment Manager with Australian life science fund, Bioscience Managers and a senior manager at Hexima Limited.   He has a PhD in Biochemistry and was awarded the prestigious Nancy Millis award for the most outstanding thesis for the Faculty of Science, Technology and Engineering in 2010.  He was an Alexander von Humbolt Research Fellow at the University of Cologne.  He has an MBA from Melbourne Business School.

Phillip Hains

Chief Financial Officer & Company Secretary
Read full bio

Phillip Hains

Chief Financial Officer & Company Secretary

Phillip is a Chartered Accountant operating a specialist public practice, ‘The CFO Solution’.  The CFO Solution focuses on providing back office support, financial reporting and compliance systems for listed public companies (particularly biotechnology companies).  Phillip has over 25 years experience in providing businesses with accounting administration, compliance and general management services.

Professor David Mozley

Chief Medical Officer & Scientific Advisory Board Chair
Read full bio

Professor David Mozley

Chief Medical Officer & Scientific Advisory Board Chair

David is a Professor of Nuclear Medicine with 30+ years in the nuclear medicine field. He was most recently at Cornell University where he was Chief of Nuclear Medicine and single-site Principal Investigator for first-in-human pharmaceutical industry contracts from three different companies using novel radiopharmaceuticals as major endpoints.  He was also the Physician Sponsor of 10 investigational new drug applications.  At University Pennsylvania he was PI awarded more than $8M in NIH RO1 grants relating to radiopharmaceutical development.  He has participated in over 60 clinical trials at Eli Lily and over 100 trials at Merck in novel radiopharmaceutical development.  Previously he was at Endocyte as Vice President of Imaging, coordinating efforts to take imaging based theranostics to market.  He has co-authored more than 100 peer-reviewed publications mostly focused on radiopharmaceutical development and is widely renowned as a Board Certified physician.

Professor Eric Aboagye

Read full bio

Professor Eric Aboagye

Eric Aboagye is Professor of Cancer Pharmacology and Molecular Imaging at Imperial College London.  He is a Fellow of the Academy of Medical Sciences and was awarded the British Institute of Radiology Sir MacKenzie Davidson Medal in 2009. His group is interested in the discovery and development of new methods for experimental and clinical cancer molecular imaging. In the past 5 years, the team has invented and translated three novel cancer diagnostics into human application.  He has acted as an advisor to GE Healthcare, GSK, Roche and Novartis.

Dr Hong Hoi Ting

Read full bio

Dr Hong Hoi Ting

Dr Hoi Ting obtained his doctorate from the University of Oxford and has built an internationally recognised career as a radiopharmaceutical and nuclear medicine expert. He has worked in both industry and academia including Oxford, Westinghouse, Johnson and Johnson, GE Healthcare and C.A.S. Shanghai National Technology Centre. He was also head consultant in nuclear medicine for CGN Nuclear Technology ( 2016 -2020 ) and a strategic consultant to ITM, a major German nuclear medicine isotopes supplier (2017-2021).  He is the founder of NanoMab Technology Limited from which Radiopharm licensed the HER-2, TROP-2, PD-L1 and PTK7 targeting technologies.

Dr Johannes Notni

Read full bio

Dr Johannes Notni

Dr Notni is an acknowledged authority in the field of integrins and nuclear medicine. Until recently he was Professor at the Technical University of Munich where his research interests included radiometal complexes for nuclear imaging and therapy, MRI contrast agents, as well as preclinical evaluation and clinical translation of innovative radiopharmaceuticals in particular integrins. For his research, he received several awards, “Radiopharmaceutical Council Young Investigator Award, 1st Prize” of the Society of Nuclear Medicine (2011) and the Innovation Prize in Medicinal and Pharmaceutical Chemistry awarded by the Gesellschaft (DPhG) (2013). In 2016, he received the EANM Springer Prize for the most cited paper in EJNMMI Research, and in 2017, the Georg von Hevesy Prize from the Deutsche Gesellschaft fur Nuklearmedizin (DGN).

Dr David Ulmert

Read full bio

Dr David Ulmert

Dr Ulmert obtained his medical degree at Lund University in Sweden. Currently at UCLA, he began a Postdoctoral Fellowship at Memorial Sloan Kettering in 2010 and has served as a Senior Research Scientist in the Medical Pharmacology Program and as the Technical Director for the Ludwig Center for Cancer Immunotherapy since 2014. Dr Ulmert’s clinical research is focused on the study of risk factors and biomarkers related to clinically diagnosed prostate cancer and definitive end-points in non-screened cohorts. The overarching goal is to apply these specific tissue targeting vehicles for multimodal molecular imaging strategies, as well as for carriers of therapeutic agents.

Dr Sara Hurvitz

SAB
Read full bio

Dr Sara Hurvitz

SAB

Dr Hurvitz is Professor of Medicine at UCLA, co-director of the Santa Monica-UCLA Outpatient Oncology Practice, Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Centre at UCLA and Director Breast Oncology. She earned her MD from the University of Southern California and served her internship/residency at UCLA. She received board certification in internal medicine, hematology and medical oncology. Dr Hurvitz has won numerous awards over the past few years, among them the Marni Levine Memorial Breast Cancer Research Award 2008 through 2015. She has an active clinical practice specialising in the treatment of women with breast cancer. She is involved in designing, implementing and leading multiple national and international clinical trials testing new targeted therapies and also leads the preclinical evaluation of novel breast cancer targets in the Translation Oncology Research Laboratory at UCLA.

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.